Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 12/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4035323 | 0.99 | MMP3 (0.39) | MMP3MMP12HTR1ADRD2DRD4 | |
| SCHEMBL13909016 | 0.85 | CRHR1 (0.48) | MMP3MMP12HTR1ADRD2DRD4 | |
| SCHEMBL3775689 | 0.81 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL4032505 | 0.77 | CRHR1 (0.43) | MMP3MMP12CRHR1CHRM1HDAC1 | |
| SCHEMBL4038331 | 0.76 | CRHR1 (0.42) | MMP3MMP12CRHR1CHRM1HDAC1 | |
| SCHEMBL5848399 | 0.73 | MYC (0.37) | HTR1ADRD2DRD4DRD3CRHR1 | |
| SCHEMBL5847449 | 0.72 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL4034627 | 0.72 | MMP3 (0.41) | MMP3MMP12HTR1ADRD2DRD4 | |
| SCHEMBL4036670 | 0.72 | CRHR1 (0.41) | MMP3MMP12CRHR1CHRM1 | |
| Hydrochloric Acid SCHEMBL4035325 | 0.71 | KCNH3 (0.42) | MMP3MMP12HTR1ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555265-B1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | EISAI CO.LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1555265-A1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | Eisai Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | CRHR1, MC2R, CRH | MMP3 1834/4885MMP12 3639/4885HTR1A 50/4885 |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | MC2R, CRHR1, CRHR2 | MMP3 1911/4885MMP12 2926/4885HTR1A 44/4885 |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | MC2R, CRHR1, CRHR2 | MMP3 2115/4885MMP12 3041/4885HTR1A 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.